Jubilant Ingrevia delivers 14-quarter high revenue in Q4 FY26 as margins strengthen across biz
The company highlighted continued demand strength and pricing resilience despite global disruptions
The company highlighted continued demand strength and pricing resilience despite global disruptions
Growth was broad-based across segments
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Additionally, an MoU was signed between the Dental Council of India and Quality Council of India for the assessment and rating of undergraduate dental colleges
Company to open new headquarters in 2024
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Subscribe To Our Newsletter & Stay Updated